Table 1.

Summary of published studies of G-CSF therapy in stroke patients.

Author (year)	Trial design/phase	G-CSF regimen	Time after stroke	Patients (intervention/control)	Comments
Floel et al. (2011)	Randomized controlled trial	10 μg/kg s/c for 10 days	4 months after	21 Intervention 20 Placebo	Feasibility and safe and reasonable tolerable in chronic stroke patients
Schäbitz et al. (2010)	Randomized, placebo-controlled	30 μg/kg, 90 μg/kg, 135 μg/kg, 180 μg/kg	Within 12 hours	14/ Placebo 8/30 μg/kg 7/90 μg/kg 8/135 μg/kg 7/180 μg/kg	Well tolerated even in higher doses and Treatment effect in patients with higher volume of lesion size (˃14–17 cm3) at baseline
Shyu et al. (2006)	Single blind controlled/pilot	15 μg/kg/day s/c for 5 days	Within 7 days	7 Intervention 15 μg/kg/day s/c for 5 days 3 Control	No thrombotic complications, and improved outcome in G-CSF group NIHSS 59% in G-CSF group, 36% in controls group BI 120% in G-CSF group, and 60% in controls group
Sprigg et al. (2006)	Double-blind placebo-controlled/pilot	Dose escalation 1–10 μg/kg s/c for 1 or 5 days	7–30 days	12/Placebo 4/1 μg/kg (single dose) 4/3 μg/kg (single dose) 4/10 μg/kg (single dose) 4/1 μg/kg (five dose) 4/3 μg/kg (five dose) 4/10 μg/kg (five dose)	No difference in SAEs although non significant increase in infection rates in active group Significant increase in CD-34+ with 10 μg/kg (five dose) at day five
Zhang (2006)	Double-blind placebo-controlled/pilot	2  μg/kg/day s/c for 5 days	Within 7 days	15  Intervention 30  Control	No difference in adverse events reported and significant reduction in NIHSS